Inside the battle to end the Aids pandemic in the face of Trump’s cuts
Inside the battle to end the Aids pandemic in the face of Trump’s cuts is drawing significant interest across the industry.
Rachel Hagan speaks to some of researchers behind the push for a full HIV vaccine – whose trial had to be saved after the US slashed its grant – about the cost of the delay, and lays out the warnings it provides for the current rollout of the ‘transformational’ preventative jab lenacapavir
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Millions with diabetes could swap daily jabs for life
- The ePlane Company Partners With NVIDIA To Develop India's First Electric Air Taxi
- Digital Overload in Spain: Is the Country Reaching Peak Social Media?
- Binarly Announces Leadership Transition as Enterprise Demand Accelerates for Supply-Chain Security
Source: Original →